CClinicalTrials.gg
Not yet recruitingNCT06582667PENG BlockUpdated Sep 3, 2024

Assessing the Effectiveness and Safety of Pericapsular Nerve Group (PENG) Block in Hip Fracture Patients on Antithrombotic Therapy

An interventional study of PENG block in Hip Fracture, Antithrombotic Therapy and PENG Block, sponsored by Alexandria University. Not yet recruiting at 1 site in Egypt. Open to participants aged 65 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-09-03.

Sponsored by Alexandria University · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 8 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
65 Years to 85 Years
Sex
All
01

Study summary

PENG block will be done on patients with hip fracture either receiving antithrombotic therapy or not under ultrasound guidance

Read the detailed description

Patients will be randomized into two groups:

Group A (Antithrombotic Therapy Group): 50 Patients on continuous antithrombotic therapy will receive BENG block.

Group C (Control Group): 50 Patients without antithrombotic therapy will receive BENG block.

Intervention:

PENG Block: Standardized administration of the PENG block will be performed by experienced anesthesiologists for both groups using ultrasound device.

The patients will be subjected to standard monitoring and received nasal cannula oxygen (2 L/min). Midazolam (1-2 mg) will be administered intravenously for light sedation.

Under sterile conditions, a low-frequency curvilinear probe of ultrasound (SonoSite S-Nerve Machine, Fujifilm) is initially placed in a transverse plane over the anterior inferior iliac spine, and is then rotated parallel to the pubic ramus to obtain a short-axis view of the iliopsoas muscle and tendon lying on the ramus pubic adjacent to the iliopubic eminence. After skin infiltration with 1-3 mL 1% lidocaine, a 23 G, 70 mm insulated block needle is inserted in-plane in a lateral-to- medial direction to place the tip in the musculofascial plane between the psoas tendon and the pubic ramus. A total of 20 mL 0.5% bupivacaine (AstraZeneca, EGYPT) is injected slowly in 5 mL increments with intermittent aspiration and under constant ultrasound surveillance for adequate fluid spread. Thirty minutes after the block completion, standardized endotracheal general anesthesia is induced with propofol (2-2.5 mg/kg), fentanyl (0.5-1,5 μg/kg), and atracurium (0.5 mg/kg).maintenance of anesthesia is done with sevoflurane (2-2.5%) with o2and air 60:40% Antithrombotic Management: Clear protocols for managing antithrombotic therapy in Group A will be implemented, considering perioperative bleeding risk

02

Conditions studied

  • Hip Fracture
  • Antithrombotic Therapy
  • PENG Block

Keywords

  • antithrombotic therapy
  • PENG block
03

In context

Fractures, Bone

2,261 studies on the registry are indexed under Fractures, Bone; 325 are open to participants now.

This study's planned enrollment of 100 is above the median of 69 across 1,482 interventional studies indexed under Fractures, Bone.

Browse Fractures, Bone studies →

Lead sponsor

Alexandria University is the lead sponsor of 570 studies on the registry; 126 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 65 years or older
  • diagnosis of hip fracture
  • scheduled for surgical intervention within 48 hours
  • Informed consent obtained.

Exclusion criteria

Exclusion Criteria:

  • Allergy to local anesthetics,
  • Contraindications to the PENG block
  • inability to provide informed consent.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    group A: PENG block in hip fracture with antithrombotic therapy

    50 patients will receive US guided PENG block and on antithrombotic therapy in hip fracture

    Procedure: PENG block

  • Experimental
    group C: PENG block in hip fracture without antithrombotic therapy

    50 patients will receive US guided PENG block without antithrombotic therapy in hip fracture

    Procedure: PENG block

Interventions

  • ProcedurePENG block

    US guided PENG block in hip fracture without anti thrombotic therapy

    Also known as: US guided PENG block in hip fracture with anti thrombotic therapy

06

What researchers measure

Primary outcomes

  1. Incidence of Hematoma Formation

    The occurrence and severity of hematomas at the PENG block site. Measurement: Regular clinical examinations and imaging studies to assess for hematoma formation.

    Time frame: first 48 hours postintervention

  2. Bloody Tab on the Needle:

    Presence of blood on the needle during the performance of the PENG block.

    Time frame: immediately during the procedure ( first 10 minutes after PENG block)

  3. Rest and mobilization pain by numerical rating scale

    post intervention to be assessed 0-10

    Time frame: 1 hour and 6 hours after surgery, on the same day of surgery (D 0) and first day postoperative(D 1) at 8 a.m., 1 p.m. and 6 p.m.

Secondary outcomes

  1. Incidence of Nerve Injury

    Any signs of sensory or motor deficits, paresthesia, or neuropathic pain related to nerve injury or compression due to hematoma formation.

    Time frame: after performing the block ( 12 hours after surgery) and subsequent assessments on the next 48 hours

  2. Postoperative quadriceps strength

    Quadriceps strength is assessed using the knee extension Test and Oxford muscle strength grading with grouped scores of intact (5/5), reduced (1-4/5) and absent (0/5).

    Time frame: first day postoperative postoperative (12 hours after surgery)

  3. The quality of Postoperative functional recovery and the variations and differences between groups will be assessed using the validated arabic version of the quality-of-recovery 15-items score (QoR-15)

    15 values score ranges from 0-150 ,excellent \>135, good \> 122 and \< 135, moderate \>90 and \< 121, poor \< 90

    Time frame: On the same day of surgery ( 12 hours after surgery) and first day postoperative

  4. - Perioperative opiate use

    will be calculated over 48 hours in milligrams

    Time frame: from the end of surgery to 48 hours postoperative

  5. length of hospital stay in days

    the number of days spent in the hospital will be calculated at the date of discharge the starting day is the date of admission called day 1 and all days spent in the hospital will be counted till the day of going home and this expected to be from 3-10 days after operation

    Time frame: from the date of admission to the date of discharge

07

Study locations

1 site
08

References and documents

Publications

  • Giron-Arango L, Peng PWH, Chin KJ, Brull R, Perlas A. Pericapsular Nerve Group (PENG) Block for Hip Fracture. Reg Anesth Pain Med. 2018 Nov;43(8):859-863. doi: 10.1097/AAP.0000000000000847. PubMed 30063657 ↗

Individual participant data

Plan to share: Yes — i would like to share my data with other researchers for more citations

Supporting information: Study protocol, Sap, Icf

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06582667
Lead sponsor
Alexandria University
Responsible party
Sponsor
First posted
Sep 3, 2024
Start date
Sep 17, 2024 (estimated)
Primary completion
Jan 17, 2025 (estimated)
Completion
Apr 17, 2025 (estimated)
Last update
Sep 3, 2024

Study contacts

Wessam El-amrawy, myself
Contact
wesam.amrawy@alexu.edu.eg
01280998606
tarek ismail, study director
Contact
drtarek.anesth@gmail.com
01001467166

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion